News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,175 Results
Type
Article (39649)
Company Profile (271)
Press Release (653255)
Section
Business (204898)
Career Advice (2015)
Deals (35505)
Drug Delivery (91)
Drug Development (81098)
Employer Resources (168)
FDA (16145)
Job Trends (14874)
News (346051)
Policy (32570)
Tag
Academia (2548)
Alliances (49626)
Alzheimer's disease (1299)
Approvals (16109)
Artificial intelligence (174)
Bankruptcy (356)
Best Places to Work (11632)
Biotechnology (190)
Breast cancer (205)
Cancer (1559)
Cardiovascular disease (121)
Career advice (1679)
CAR-T (108)
Cell therapy (318)
Clinical research (65130)
Collaboration (589)
Compensation (313)
COVID-19 (2571)
C-suite (136)
Data (1494)
Diabetes (192)
Diagnostics (6223)
Earnings (85192)
Employer resources (146)
Events (110915)
Executive appointments (504)
FDA (16934)
Funding (530)
Gene therapy (221)
GLP-1 (630)
Government (4356)
Healthcare (18760)
Infectious disease (2668)
Inflammatory bowel disease (118)
Interviews (309)
IPO (16439)
Job creations (3661)
Job search strategy (1431)
Layoffs (432)
Legal (7907)
Lung cancer (230)
Manufacturing (217)
Medical device (13251)
Medtech (13256)
Mergers & acquisitions (19344)
Metabolic disorders (504)
Neuroscience (1670)
NextGen: Class of 2025 (6542)
Non-profit (4484)
Northern California (1890)
Obesity (286)
Opinion (192)
Patents (135)
People (57008)
Phase I (20295)
Phase II (28691)
Phase III (21360)
Pipeline (620)
Postmarket research (2563)
Preclinical (8586)
Radiopharmaceuticals (239)
Rare diseases (295)
Real estate (5940)
Regulatory (21868)
Research institute (2318)
Resumes & cover letters (350)
Southern California (1641)
Startups (3620)
United States (16912)
Vaccines (583)
Weight loss (197)
Date
Today (127)
Last 7 days (575)
Last 30 days (2245)
Last 365 days (34961)
2025 (2165)
2024 (35329)
2023 (40179)
2022 (51290)
2021 (55836)
2020 (54160)
2019 (46644)
2018 (35127)
2017 (32227)
2016 (31634)
2015 (37712)
2014 (31456)
2013 (26501)
2012 (28772)
2011 (29426)
2010 (27526)
Location
Africa (716)
Arizona (204)
Asia (37629)
Australia (6161)
California (4318)
Canada (1578)
China (369)
Colorado (196)
Connecticut (207)
Europe (80642)
Florida (619)
Georgia (150)
Illinois (425)
Indiana (246)
Maryland (689)
Massachusetts (3330)
Michigan (185)
Minnesota (317)
New Jersey (1210)
New York (1235)
North Carolina (791)
Northern California (1890)
Ohio (159)
Pennsylvania (1010)
South America (1096)
Southern California (1641)
Texas (637)
Utah (123)
Washington State (430)
693,175 Results for "nielsen biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts
Nielsen BioSciences, Inc. today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN ® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.
March 5, 2024
·
3 min read
Business
Vial Partners with Nielsen BioSciences, Inc. in Phase III Clinical Trial for the Treatment of Common Warts
Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to study the safety and efficacy of CANDIN® for the treatment of common warts.
June 14, 2023
·
5 min read
Business
Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts
Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).
May 16, 2023
·
5 min read
Press Releases
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
January 14, 2025
·
1 min read
Press Releases
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
January 6, 2025
·
5 min read
Press Releases
Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer
January 10, 2025
·
4 min read
Press Releases
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
December 24, 2024
·
5 min read
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Press Releases
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
January 14, 2025
·
4 min read
Press Releases
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
December 19, 2024
·
1 min read
1 of 69,318
Next
